Comparative Pharmacology
Head-to-head clinical analysis: MENTAX TC versus OXISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX TC versus OXISTAT.
MENTAX-TC vs OXISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
Oxiconazole is an azole antifungal that inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply a thin layer to affected area once daily for 2-4 weeks.
Apply topically once daily for 2 weeks (tinea pedis, tinea cruris, tinea corporis) or 4 weeks (tinea versicolor).
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing.
Terminal elimination half-life is 20–30 hours, supporting once-daily topical application.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination accounts for ~75% of dose.
Category C
Category C
Topical Antifungal
Topical Antifungal